Image Description

INVESTORS
& MEDIA

circle

PRESS RELEASES

  • Webcast Image Webcast
    X Q3 2017 Cytokinetics, Inc. Earnings Conference Call
    Oct 26, 2017 at 4:30 PM EDT

    Q3 2017 Cytokinetics, Inc. Earnings Conference Call
    Oct 26, 2017 at 4:30 PM EDT
Date Title and Summary
Toggle Summary Cytokinetics Added to S&P SmallCap 600
SOUTH SAN FRANCISCO, Calif. , April 21, 2017 (GLOBE NEWSWIRE) -- Cytokinetics (Nasdaq:CYTK) today announced it has been selected for addition to the S&P SmallCap 600 GICS Biotechnology Sub-Industry Index. The index, a member of the Dow Jones Total Stock Market Indices family, is designed to
Toggle Summary Cytokinetics and Royalty Pharma Announce $100 Million Transaction for Omecamtiv Mecarbil
Royalty Pharma Buys 4.5 Percent Royalty on Worldwide Sales for $90 Million Plus $10 Million Equity in Cytokinetics Cytokinetics Agrees to Exercise Option to Co-Fund Phase 3 Development Program Under Collaboration with Amgen for Increased Royalty and Co-Promotion Rights in North America Company to
Toggle Summary Cytokinetics and the ALS Association Renew Partnership to Advance the Fight Against ALS
SOUTH SAN FRANCISCO, Calif., and WASHINGTON, May 03, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) and The ALS Association today announced the continuation of their partnership in the fight against ALS which includes Cytokinetics’ renewal of its Gold Level Sponsorship of the National
Toggle Summary Cytokinetics Announces Additional Results From COSMIC-HF Presented at ACC.17
SOUTH SAN FRANCISCO, Calif. , March 20, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that additional results from COSMIC-HF ( C hronic O ral S tudy of M yosin Activation to I ncrease C ontractility in H eart F ailure), a Phase 2 trial evaluating omecamtiv mecarbil in
Toggle Summary Cytokinetics Announces Additional Results From COSMIC-HF to be Presented at the HFSA 21st Annual Scientific Meeting
SOUTH SAN FRANCISCO, Calif. , Sept. 11, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that additional results from COSMIC-HF ( C hronic O ral S tudy of M yosin Activation to I ncrease C ontractility in H eart F ailure), a Phase 2 trial evaluating omecamtiv mecarbil in
Toggle Summary Cytokinetics Announces Baseline Data From First Cohort of Phase 2 Clinical Trial of CK-2127107 in Patients With SMA
Patient Demographics Presented at Cure SMA 2017 Annual SMA Conference SOUTH SAN FRANCISCO, Calif. , July 05, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that data relating to patient baseline characteristics and the reasons for patient screen failure, both from the
Toggle Summary Cytokinetics Announces Dosing of First Patient in Japan in GALACTIC-HF, Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure
Company Earns $10 Million Milestone Payment from Amgen SOUTH SAN FRANCISCO, Calif. , Sept. 19, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that the first patient has been dosed in Japan in GALACTIC-HF ( G lobal A pproach to L owering A dverse C ardiac Outcomes
Toggle Summary Cytokinetics Announces Orphan Drug Designation for CK-2127107 for the Treatment of Spinal Muscular Atrophy
SOUTH SAN FRANCISCO, Calif. , May 15, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration ( FDA ) has granted orphan drug designation to CK-2127107 for the potential treatment of
Toggle Summary Cytokinetics Announces Positive Results From Phase 2 Clinical Trial of Omecamtiv Mecarbil in Japanese Patients With Heart Failure
Data Supports Inclusion of Japan in GALACTIC-HF Company is Eligible to Earn $10 Million Milestone Payment from Amgen upon First Patient Dosing in Japan in Phase 3 Outcomes Trial SOUTH SAN FRANCISCO, Calif. , Aug. 02, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced
Toggle Summary Cytokinetics Announces Preclinical Data for CK-2127107 Presented at MDA Scientific Conference
Next-Generation Fast Skeletal Troponin Activator Improves Muscle Function in Mouse Models of Spinal Muscular Atrophy SOUTH SAN FRANCISCO, Calif. , March 22, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that preclinical data for CK-2127107 were presented at the MDA
Toggle Summary Cytokinetics Announces Presentation of Additional Results from COSMIC-HF at ACC.17
SOUTH SAN FRANCISCO, Calif. , March 06, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that additional results from COSMIC-HF ( C hronic O ral S tudy of M yosin Activation to I ncrease C ontractility in H eart F ailure), a Phase 2 trial evaluating omecamtiv mecarbil in
Toggle Summary Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at the HFSA 21st Annual Scientific Meeting
Effects of Omecamtiv Mecarbil Were Similar in Patients with Ischemic and Non-Ischemic Heart Failure SOUTH SAN FRANCISCO, Calif. , Sept. 18, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that additional results from COSMIC-HF ( C hronic O ral S tudy of M yosin
Toggle Summary Cytokinetics Announces Presentations at the Cure SMA 2017 Annual SMA Conference
SOUTH SAN FRANCISCO, Calif. , June 23, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced presentations at the Cure SMA 2017 Annual SMA Conference from June 29 - July 2, 2017 in Orlando, FL. In an oral presentation on July 1 , Stacy Rudnicki , M.D., Director, Clinical
Toggle Summary Cytokinetics Announces Pricing of Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif. , May 08, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced the pricing of an underwritten public offering of 5,260,000 shares of its common stock at a price to the public of $14.25 per share, before underwriting discounts and commissions.
Toggle Summary Cytokinetics Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif. , May 08, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced plans to offer, subject to market and other conditions, $75,000,000 of its common stock in an underwritten public offering. There can be no assurance as to whether or when the
Toggle Summary Cytokinetics Announces Results from Dose Escalation Phase of COSMIC-HF Presented at Heart Failure 2017
SOUTH SAN FRANCISCO, Calif. , May 01, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that results from the dose escalation phase of COSMIC-HF ( C hronic O ral S tudy of M yosin Activation to I ncrease C ontractility in H eart F ailure), a Phase 2 trial evaluating
Toggle Summary Cytokinetics Announces Start of FORTITUDE-ALS, a Phase 2 Clinical Trial of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis
SOUTH SAN FRANCISCO, Calif. , July 27, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced the start of FORTITUDE-ALS, F unctional O utcomes in a R andomized T rial of I nvestigational T reatment with CK-2127107 to U nderstand D ecline in E ndpoints – in ALS.
Toggle Summary Cytokinetics Announces Start of Phase 1b Clinical Trial of CK-2127107 in Elderly Subjects With Limited Mobility
Trial Designed to Assess Effects of Skeletal Muscle Activation on Measures of Muscle Strength and Endurance Under Collaboration with Astellas SOUTH SAN FRANCISCO, Calif. , June 29, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced the start of a Phase 1b,
Toggle Summary Cytokinetics Announces Start of Second Cohort in Phase 2 Clinical Trial of CK-2127107 in Patients With Spinal Muscular Atrophy
Data Monitoring Committee Agrees to Proceed to Higher Dose Cohort One of Four Clinical Trials in 2017 under Astellas Collaboration SOUTH SAN FRANCISCO, Calif. , March 29, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that the second cohort of the Phase 2 clinical trial
Toggle Summary Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day
SOUTH SAN FRANCISCO, Calif. , Feb. 28, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that it is joining the global initiative with the European Organisation for Rare Diseases (EURORDIS) and the National Organization for Rare Disorders (NORD) to raise awareness of Rare
Toggle Summary Cytokinetics to Announce First Quarter Results on April 27, 2017
SOUTH SAN FRANCISCO, Calif. , April 13, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that it is scheduled to report first quarter results on Thursday, April 27, 2017 at 4:00 PM Eastern Time . Following the announcement, Cytokinetics’ senior management will host a
Toggle Summary Cytokinetics to Announce Fourth Quarter Results on February 16, 2017
SOUTH SAN FRANCISCO, Calif. , Feb. 03, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that it is scheduled to report fourth quarter results on Thursday, February 16, 2017 at 4:00 PM Eastern Time . Following the announcement, Cytokinetics’ senior management will host a
Toggle Summary Cytokinetics to Announce Second Quarter Results on August 2, 2017
SOUTH SAN FRANCISCO, Calif. , July 26, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that it is scheduled to report second quarter results on Wednesday, August 2, 2017 at 4:00 PM Eastern Time . Following the announcement, Cytokinetics’ senior management will host a
Toggle Summary Cytokinetics to Announce Third Quarter Results on October 26, 2017
SOUTH SAN FRANCISCO, Calif. , Oct. 12, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that it is scheduled to report third quarter results on October 26, 2017 at 4:00 PM Eastern Time . Following the announcement, Cytokinetics’ senior management will host a
Toggle Summary Cytokinetics to Hold Annual Meeting of Stockholders
SOUTH SAN FRANCISCO, Calif. , May 11, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that its Annual Meeting of Stockholders will be held on Thursday, May 18, 2017 at 10:30 AM Pacific Time at the Embassy Suites Hotel , located at 250 Gateway Boulevard in South San
Toggle Summary Cytokinetics to Participate in Panel on Neuromuscular Disorders at the JMP Securities Life Sciences Conference
SOUTH SAN FRANCISCO, Calif. , June 13, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that Robert I. Blum , President and Chief Executive Officer, is scheduled to participate in a panel discussion on Neuromuscular Disorders at the JMP Securities 2017 Life Sciences
Toggle Summary Cytokinetics to Present at March Investor Conferences
SOUTH SAN FRANCISCO, Calif. , Feb. 27, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) announced today that Robert I. Blum , President and Chief Executive Officer, is scheduled to present a corporate update at the following investor conferences: Cowen and Company 37 th  Annual Health Care
Toggle Summary Cytokinetics to Present at September Investor Conferences
SOUTH SAN FRANCISCO, Calif. , Sept. 05, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) announced today that Robert I. Blum , President and Chief Executive Officer, is scheduled to present a corporate update at the following investor conferences: Morgan Stanley 15 th Annual Global
Toggle Summary Cytokinetics to Present at the 16th Annual Needham Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , March 29, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that Robert I. Blum , President and Chief Executive Officer, is scheduled to present a corporate update at the 16 th Annual Needham Healthcare Conference on Wednesday, April 5, 2017 at
Toggle Summary Cytokinetics, Inc. Reports First Quarter 2017 Financial Results
Data Monitoring Committee for VITALITY-ALS Recommended Continuation of Phase 3 Trial; Results Expected in Q4 Sale of Royalty on Omecamtiv Mecarbil to Royalty Pharma  Contributed to Increased Cash Balance Expansion of Clinical Trials Program for CK-2127107 in Collaboration with Astellas SOUTH SAN
Toggle Summary Cytokinetics, Inc. Reports Fourth Quarter 2016 Financial Results
Company Provides 2017 Financial Guidance and Expected Milestones Phase 3 Results Expected from VITALITY-ALS in Q4 2017 SOUTH SAN FRANCISCO, Calif. , Feb. 16, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) reported total revenues for the fourth quarter of 2016 were $33.1 million ,
Toggle Summary Cytokinetics, Inc. Reports Second Quarter 2017 Financial Results
Results Expected from VITALITY-ALS, Our Phase 3 Clinical Trial of Tirasemtiv, in Q4 2017 CK-2127107 Advancing in Four Clinical Trials Under Our Collaboration with Astellas Omecamtiv Mecarbil Phase 3 Clinical Trial Proceeding on Plan in GALACTIC-HF Under Our Collaboration with Amgen SOUTH SAN
Toggle Summary Origent Data Sciences and Cytokinetics Advance Collaboration Intended to Validate Predictive Analytics Model in ALS
Research Aimed at Accelerating Conduct of Clinical Trials VIENNA, Va. AND SOUTH SAN FRANCISCO, Calif., March 23, 2017 (GLOBE NEWSWIRE) -- Origent Data Sciences, Inc. (Origent) and Cytokinetics, Inc. (Nasdaq:CYTK) today announced the advancement of their research collaboration to prospectively